Research & development increased 29.6%
Research & development changed +29.6% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed +29.6% from the comparable as-filed period.
Reported total debt changed -3.3% from the comparable as-filed period. The change ranks at the 100th percentile of 7 prior comparable changes.
Gross debt changed -3.3% from the comparable as-filed period. The change ranks at the 100th percentile of 7 prior comparable changes.
Cash & equivalents changed +68.1% from the comparable as-filed period.
Current ratio changed -56.2% from the comparable as-filed period.
Current liabilities changed +181.4% from the comparable as-filed period.
Working capital / assets changed -660 basis points from the comparable as-filed period.
Net debt changed -72.4% from the comparable as-filed period.
Cash / debt changed +128883 basis points from the comparable as-filed period.
Stock-based compensation changed +26.8% from the comparable as-filed period.
Trade receivables changed +19.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Total assets changed +26.2% from the comparable as-filed period.
Operating cash flow changed -3.5% from the comparable as-filed period.
Current assets changed +23.3% from the comparable as-filed period.
Capital expenditure changed +1283.5% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a low base.
Working capital changed +12.0% from the comparable as-filed period.
Debt / assets changed -12 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.